FDA set to review Sanofi’s isatuximab for multiple myeloma
Multiple myeloma is the second most common hematologic malignancy, affecting more than 138,0002 people worldwide.
Read More
Tag: CD38
NICE approves CDF funding for Janssen’s Darzalex
The National Institute for Health and Care Excellence (NICE) is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund (CDF) for some adults with previously treated multiple myeloma.
Read More
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
